Content Library

Welcome to the World ADC media hub. Here you will find exclusive insights from our 2024 expert speakers, past presentations and articles plus much more. 

Email to submit for approval content that you wish to share.

Speaker Interview Cover

Exclusive Speaker Interview

Ahead of the 13th World ADC London, we caught up with Mark Frigerio, Vice President, Chemistry, Bicycle Therapeutics for his exclusive insights on the great significance of the last 12 months for the ADC field, the exciting rise of novel format conjugates, and his take on what the future holds for ADC professionals.

By Hanson Wade


CDMO's in the Preclinical ADC Space: A Benchmarking Study

Antibody-Drug Conjugates (ADC) have progressed a long way as a modality in recent times, culminating in a flurry of new drug approvals over the past couple of years. However, despite this progress, there is little in the public domain detailing how service providers are used in this space, particularly for assets at the preclinical stage where the announcement of partnerships is rare.

At Hanson Wade Intelligence, we sought to shed light on this under-represented area. We carried out a survey of 51 preclinical ADC developers, as well as carrying out in-depth interviews to support the sentiment uncovered in the survey.

So whether you are a developer, a service provider, or an observer of this space, this report will add to your understanding and provide some well-needed clarity to the preclinical ADC space. We uncover the major players, the importance of company size and molecule toxicity, and the traits that developers consider the most important when outsourcing their preclinical ADC assets.

By Hanson Wade Market Research



SWOT Analysis of Trodelvy (sacituzumab govitecan-hziy)

By Hanson Wade



SWOT Analysis of Enhertu (trastuzumab deruxtecan)

By Hanson Wade



Covid-19 Perspectives 

By the Medicine Maker, World ADC Europe Media Partner


ADC Presentation 1

OligoTEAs: A Platform for the Design of Multifunctional Antibody Conjugates and Quantification of Intracellular Processes

By Christopher A. Alabi, Associate Professor at Cornell University


ADC Presentation 2

Getting Small to Enhance Targeting Small Molecule Therapeutics for the Imaging and the Treatment of Solid Tumors

By Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philochem


ADC Magazine 2.0

ADC Magazine

Three Speaker Interviews with:

  • Phil Howard, Spirogen
  • Thomas Pillow, Genentech
  • Hillary Schuessler, GSK

Stats & Facts from Beacon Targeted Therapies on:

  • Alternative Formats
  • ADCs in Combination
  • The Clinical Landscape
World ADC London Social Card (2)